AUC-Guided Vancomycin Dosing in Adolescent Patients With Suspected Sepsis

被引:24
|
作者
Lanke, Shankar [1 ]
Yu, Tian [2 ]
Rower, Joseph E. [2 ]
Balch, Alfred H. [2 ]
Korgenski, E. Kent [3 ]
Sherwin, Catherine M. [2 ,4 ]
机构
[1] Univ Findlay, Dept Pharmaceut Sci, Findlay, OH USA
[2] Univ Utah, Dept Pediat, Div Clin Pharmacol, Salt Lake City, UT USA
[3] Intermt Healthcare, Pediat Clin Program, Salt Lake City, UT USA
[4] Univ Utah, Coll Pharm, Dept Pharmacol & Toxicol, Salt Lake City, UT 84112 USA
来源
JOURNAL OF CLINICAL PHARMACOLOGY | 2017年 / 57卷 / 01期
关键词
population pharmacokinetics; pharmacodynamics; vancomycin; pediatrics; adolescents; CHILDREN; PHARMACOKINETICS;
D O I
10.1002/jcph.782
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Vancomycin is a first-line treatment for -lactam-resistant Gram-positive bacterial infections. Understanding the pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of vancomycin in an adolescent population is of clinical importance in this often overlooked pediatric population. This retrospective study investigated vancomycin PK-PD in an adolescent cohort (12 to 18 years of age) of 463 patients (57% male, 81% white) admitted to the Intermountain Healthcare System between January 2006 and December 2013. Population PK modeling was performed in NONMEM 7.3. Vancomycin PK was well described with a 1-compartment model that identified both body weight (WT) and creatinine clearance (CRCL) as covariates significantly impacting vancomycin disposition. The model was then utilized to determine dosing strategies that achieved the targeted area under the 24-hour time curve vs minimum inhibitory concentration (AUC(0-24)/MIC) ratio of 400. Additionally, these data were correlated with minimum steady-state concentrations (C-ss,C-min) to find an acceptable target trough concentration range in adolescents. This analysis demonstrated that C-ss,C-min ranging from 10 to 12.5 mg/L were highly predictive of achieving an AUC(0-24)/MIC 400 when the MIC was 1 mg/L. These results suggest that the target trough concentration for adolescents may be lower than that for adults.
引用
收藏
页码:77 / 84
页数:8
相关论文
共 50 条
  • [21] Vancomycin dosing in hemodialysis patients
    Castellano, I.
    Gonzalez Castillo, P. M.
    Covarsi, A.
    Martinez Sanchez, J.
    Suarez Santisteban, M. A.
    Gallego, S.
    Marigliano, N.
    NEFROLOGIA, 2008, 28 (06): : 607 - 612
  • [22] Vancomycin Dosing in Neutropenic Patients
    Haeseker, Michiel B.
    Croes, Sander
    Neef, Cees
    Bruggeman, Cathrien A.
    Stolk, Leo M. L.
    Verbon, Annelies
    PLOS ONE, 2014, 9 (11):
  • [23] Vancomycin dosing in patients with obesity
    Erstad, Brian L.
    Matthias, Kathryn R.
    Nix, David E.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2022, 79 (22) : 2058 - 2069
  • [24] Assessment of the Implementation of AUC Dosing and Monitoring Practices With Vancomycin at Hospitals Across the United States
    Bradley, Nicole
    Lee, Yuman
    Sadeia, Muaz
    JOURNAL OF PHARMACY PRACTICE, 2022, 35 (06) : 864 - 869
  • [25] Comment: Outcomes Associated with AUC24/MIC Nomogram Dosing of Vancomycin REPLY
    Michalets, Elizabeth Landrum
    Pounders, Cristy L.
    Hollis, Sarah J.
    Sutherland, Susan
    ANNALS OF PHARMACOTHERAPY, 2011, 45 (10) : 1314 - 1315
  • [26] Biomarker-Guided Antibiotic Duration for Hospitalized Patients With Suspected Sepsis
    Dark, Paul
    Hossain, Anower
    Mcauley, Daniel F.
    Brealey, David
    Carlson, Gordon
    Clayton, Jonathan C.
    Felton, Timothy W.
    Ghuman, Belinder K.
    Gordon, Anthony C.
    Hellyer, Thomas P.
    Lone, Nazir I.
    Manazar, Uzma
    Richards, Gillian
    Mccullagh, Iain J.
    Mcmullan, Ronan
    Mcnamee, James J.
    Mcneil, Hannah C.
    Mouncey, Paul R.
    Naisbitt, Micheal J.
    Parker, Robert J.
    Poole, Ruth L.
    Rostron, Anthony J.
    Singer, Mervyn
    Stevenson, Matt D.
    Walsh, Tim S.
    Welters, Ingeborg D.
    Whitehouse, Tony
    Whiteley, Simon
    Wilson, Peter
    Young, Keith K.
    Perkins, Gavin D.
    Lall, Ranjit
    ADAPT Sepsis Collaborators
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2024,
  • [27] COMPARISON OF VANCOMYCIN AUC VERSUS TROUGH DOSING STRATEGIES ON NEPHROTOXICITY: A META-ANALYSIS
    Crovetto, Brynna
    Brunetti, Luigi
    CRITICAL CARE MEDICINE, 2022, 50 (01) : 345 - 345
  • [28] 'Cost-benefit analysis comparing trough, two-level AUC, and Bayesian AUC dosing for vancomycin': authors' reply
    Lee, Brian V.
    Fong, Gary
    Bolaris, Michael
    Neely, Michael
    Minejima, Emi
    Kang, Amy
    Lee, Grace
    Gong, Cynthia L.
    CLINICAL MICROBIOLOGY AND INFECTION, 2021, 27 (06) : 929 - 930
  • [29] Trough-guided Versus AUC/MIC-Guided Vancomycin Monitoring: A Cost Analysis
    Morales, Ronaldo
    Tiguman, Gustavo Magno Baldin
    Juodinis, Vanessa D'Amaro
    Santos, Isabela Cristina Pinheiro de Freitas
    Leite, Fernanda Soares
    Vercelino, Jucara Guicardi
    de Lima, Bruna Diniz
    Barbosa, Livia Maria Goncalves
    CLINICAL THERAPEUTICS, 2022, 44 (09) : E91 - E96
  • [30] Achievement of vancomycin AUC targets: a study in elderly patients
    Doucey, P.
    Leclerc, V.
    Bourguignon, L.
    Goutelle, S.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2018, 32 : 56 - 56